InsidersTradesSigma
SANOFI Stock: price and directors' dealings · France · AMF
Track the SANOFI share price and the full directors' dealings record of the company, a publicly traded company based in France. Shares trade on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, SANOFI has logged 44 reports. Market capitalisation: €90.7bn. The latest transaction was reported on 7 July 2026 (Mainlevée de nantissement). Among the most active insiders: Thomas TRIOMPHE. The full history is openly available.
44
Insider Decl.
0
Thresholds
€7m
26 ops.
Buy Volume
€2m
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate SANOFI Buy (bullish), based on 23 analysts. Average price target: €96.70.
52Σ signal
Fundamental score
Ranked 3,087 of 25,443 companies
72.1
score / 100
Value75
Quality69
FCF yld7.9%
Earn yld8.6%
EV/EBITDA8.9x
ROE6.6%
Gross mgn72%
Net mgn17%
Debt/EBITDA1.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 July 2026
Declarations44 total
55,000 shares0ActionHors plateforme de négociation2026DD1125509
7,000 shares0ActionHors plateforme de négociation2026DD1123406
168.898 shares@ €59.870.0000% mcap100.0% of flowParts de fonds d'épargne salarialeHors plateforme de négociation2026DD1119588
Ideal exit: 3 Mar 2027 (T+270)
70.084 shares@ €59.870.0000% mcap67.3% of flowParts de fonds d'épargne salarialeHors plateforme de négociation2026DD1119459
Ideal exit: 3 Mar 2027 (T+270)
23.687 shares0Parts de fonds d'épargne salarialeHors plateforme de négociation2026DD1119292
Ideal exit: 25 Feb 2027 (T+270)
26.687 shares@ €76.44050.0000% mcap100.0% of flowParts de fonds d'épargne salarialeHors plateforme de négociation2026DD1119150
Ideal exit: 25 Feb 2027 (T+270)
56.194 shares@ €76.44050.0000% mcap100.0% of flowParts de fonds d'épargne salarialeHors plateforme de négociation2026DD1119152
Ideal exit: 25 Feb 2027 (T+270)
26.687 shares@ €76.440.0000% mcap100.0% of flowParts de fonds d'épargne salarialeHors plateforme de négociation2026DD1118522
Ideal exit: 25 Feb 2027 (T+270)
18,673 shares@ €77.0280.0016% mcap100.0% of flowActionEuronext Paris2026DD1116899
8,568 shares@ €77.14040.0007% mcap100.0% of flowActionEuronext Paris2026DD1116685
4,099 shares@ €77.14040.0003% mcap100.0% of flowActionEuronext Paris2026DD1116693
816 shares@ €77.14040.0001% mcap100.0% of flowActionEuronext Paris2026DD1116682
3,076 shares0ActionHors plateforme de négociation2026DD1116482
Ideal exit: 19 Feb 2027 (T+270)
16,476 shares0ActionHors plateforme de négociation2026DD1116491
Ideal exit: 19 Feb 2027 (T+270)
18,673 shares0ActionHors plateforme de négociation2026DD1116431
Ideal exit: 19 Feb 2027 (T+270)
4,581 shares0ActionHors plateforme de négociation2026DD1116440
Ideal exit: 19 Feb 2027 (T+270)
3,076 shares0ActionHors plateforme de négociation2026DD1116443
Ideal exit: 19 Feb 2027 (T+270)
15,378 shares0ActionHors plateforme de négociation2026DD1116476
Ideal exit: 19 Feb 2027 (T+270)
21,145 shares0ActionHors plateforme de négociation2026DD1116396
Ideal exit: 19 Feb 2027 (T+270)
18,673 shares0ActionHors plateforme de négociation2026DD1116398
Ideal exit: 19 Feb 2027 (T+270)
7,689 shares0ActionHors plateforme de négociation2026DD1116406
Ideal exit: 19 Feb 2027 (T+270)
207 shares@ £79.088426.1% of flowActionEuronext Paris2025DD1069155
Ideal exit: 10 Aug 2026 (T+270)
6.802 shares@ €88.279.3% of flowParts de FCPEEuronext Paris2025DD1049682
Ideal exit: 3 Mar 2026 (T+270)
500 shares@ €82.7045.9% of flowActionEuronext Paris2025DD1045002
Ideal exit: 23 Mar 2026 (T+270)
69,597 shares0ActionHors plateforme de négociation2025DD1036080
Ideal exit: 30 Jan 2026 (T+270)
25 of 44 declarations
About SANOFI
Sanofi is a French global healthcare leader focused on the discovery, development, manufacturing and commercialization of medicines and vaccines. The company is listed in Paris and identified by ISIN FR0000120578. Its investment case is built on a science-led biopharma platform with a strong emphasis on innovation across major therapeutic areas, including immunology, rare diseases, neurology, oncology and vaccines. Sanofi currently describes itself as an R&D-driven, AI-powered biopharmaceutical company, with a strategy aimed at accelerating growth through breakthrough science, pipeline expansion and the launch of new products. The company traces its roots to 1973, when it was created in France, although its heritage extends much further back through numerous predecessor businesses in healthcare whose origins date to the 18th and 19th centuries. Sanofi marked the 50th anniversary of its creation in 2023, underscoring the depth of its industrial and scientific legacy. Over time, this heritage has helped Sanofi become one of Europe’s most established healthcare groups, with a broad international footprint and a long history of corporate consolidation, research capability building and portfolio expansion. Operationally, Sanofi’s core businesses span prescription medicines, vaccines and innovative specialty therapies. Dupixent is one of the group’s flagship products and remains a major growth driver, while newer launches such as Tzield and Altuviiio are broadening the company’s commercial base. Sanofi also has a longstanding vaccine franchise, with historical strengths in injectable polio vaccines as well as influenza, meningitis and rabies vaccines. The company states that its vaccine portfolio protects hundreds of millions of people worldwide, highlighting both its scale and its public-health relevance. From a geographic standpoint, Sanofi operates globally, with a significant presence across Europe, North America and major emerging markets. Its integrated model combines research, manufacturing and commercial activities in numerous countries, supporting worldwide access to its medicines and vaccines. Recent financial updates indicate strong commercial momentum, driven by launches and key franchises. Strategically, Sanofi has also announced a shift toward a more focused, science-driven biopharma profile, including its intention to sell a controlling stake in Opella, its consumer healthcare business. This move simplifies the group’s structure and reinforces its positioning as a high-value, innovation-led pharmaceutical company.
